Intimation of the meeting of the Board of Directors of Novartis India Limited ("the company") and Closure of Trading Window to inter alia, consider and approve the Unaudited Financial Results ....
NOVARTIND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Novartis India has informed the stock exchange that its Board of Directors will meet on Wednesday, January 28, 2026, to consider and approve the Unaudited Financial Results for the quarter ended December 31, 2025 (Q3 FY26). As per the company's insider trading code, the trading window for designated persons, insiders, connected persons and their immediate relatives has been closed from January 1, 2026. The window will reopen 48 hours after the financial results are officially announced to the stock exchange. This is a standard regulatory filing under SEBI LODR Regulation 29 and does not contain any actual financial numbers.
This is a routine compliance intimation with no direct impact on shareholders or the stock price. Investors should watch for the actual Q3 FY26 results on January 28, 2026, which will provide the next meaningful update on the company's quarterly performance.